Article
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2008
Bean James, Riely Gregory J, Balak Marissa, Marks Jenifer L, Ladanyi Marc, Miller Vincent A, Pao William
Abstract excerpt
PURPOSE: Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are associated with sensitivity of lung adenocarcinomas to the EGFR tyrosine kinase inhibitors, gefitinib and erlotinib. Acquired drug resistance is frequently associated with a secondary...
Topics
- Adenocarcinoma
- Afatinib
- Aged
- Amino Acid Sequence
- Antineoplastic Agents
- Base Sequence
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- ErbB Receptors
- Erlotinib Hydrochloride
- Female
- Gefitinib
- Humans
- Immunoblotting